Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.
Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Lechmere T, Malim MH, Meynell F, Pollock E, Seow J, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree TIM, Smith CH. Mahil SK, et al. Among authors: cope ap. Lancet Rheumatol. 2021 Sep;3(9):e627-e637. doi: 10.1016/S2665-9913(21)00212-5. Epub 2021 Jul 8. Lancet Rheumatol. 2021. PMID: 34258590 Free PMC article.
Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
Ibrahim F, Lorente-Cánovas B, Doré CJ, Bosworth A, Ma MH, Galloway JB, Cope AP, Pande I, Walker D, Scott DL. Ibrahim F, et al. Among authors: cope ap. Rheumatology (Oxford). 2017 Nov 1;56(11):2004-2014. doi: 10.1093/rheumatology/kex315. Rheumatology (Oxford). 2017. PMID: 28968858 Free PMC article. Clinical Trial.
Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Bechman K, Clarke BD, Rutherford AI, Yates M, Nikiphorou E, Molokhia M, Norton S, Cope AP, Hyrich KL, Galloway JB. Bechman K, et al. Among authors: cope ap. Rheumatology (Oxford). 2019 Oct 1;58(10):1767-1776. doi: 10.1093/rheumatology/kez037. Rheumatology (Oxford). 2019. PMID: 30982886
Placebo Response in Rheumatoid Arthritis Clinical Trials.
Bechman K, Yates M, Norton S, Cope AP, Galloway JB. Bechman K, et al. Among authors: cope ap. J Rheumatol. 2020 Jan;47(1):28-34. doi: 10.3899/jrheum.190008. Epub 2019 May 1. J Rheumatol. 2020. PMID: 31043548 Free PMC article.
Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
Bechman K, Oke A, Yates M, Norton S, Dennison E, Cope AP, Galloway JB. Bechman K, et al. Among authors: cope ap. Rheumatology (Oxford). 2020 Sep 1;59(9):2563-2571. doi: 10.1093/rheumatology/kez671. Rheumatology (Oxford). 2020. PMID: 31998962 Free PMC article.
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
Bechman K, Oke A, Yates M, Norton S, Dennison E, Cope AP, Galloway JB. Bechman K, et al. Among authors: cope ap. Rheumatology (Oxford). 2021 Apr 6;60(4):2033. doi: 10.1093/rheumatology/keaa612. Rheumatology (Oxford). 2021. PMID: 33026092 Free PMC article. No abstract available.
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V, Qureshi S, Cope AP, Norton S, Galloway JB. Yates M, et al. Among authors: cope ap. Arthritis Rheumatol. 2021 May;73(5):779-788. doi: 10.1002/art.41580. Epub 2021 Mar 25. Arthritis Rheumatol. 2021. PMID: 33174384
173 results